Neuroblastoma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 221 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Neuroblastoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Neuroblastoma - Pipeline Review, H2 2014', provides an overview of the Neuroblastoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Neuroblastoma Overview 9
Therapeutics Development 10
Pipeline Products for Neuroblastoma - Overview 10
Pipeline Products for Neuroblastoma - Comparative Analysis 11
Neuroblastoma - Therapeutics under Development by Companies 12
Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 16
Neuroblastoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Neuroblastoma - Products under Development by Companies 21
Neuroblastoma - Products under Investigation by Universities/Institutes 24
Neuroblastoma - Companies Involved in Therapeutics Development 25
United Therapeutics Corporation 25
Shionogi & Co., Ltd. 26
GlaxoSmithKline plc 27
Gamida Cell Ltd. 28
BioLineRx, Ltd. 29
Novartis AG 30
Chugai Pharmaceutical Co., Ltd. 31
Teva Pharmaceutical Industries Limited 32
Progenics Pharmaceuticals, Inc. 33
Celgene Corporation 34
AEterna Zentaris Inc. 35
Lorus Therapeutics Inc. 36
Novogen Limited 37
Cleveland BioLabs, Inc. 38
Threshold Pharmaceuticals, Inc. 39
Sareum Holdings plc 40
MabVax Therapeutics, Inc. 41
Bionucleon Srl 42
Neotropix, Inc. 43
APEIRON Biologics AG 44
Sutro Biopharma, Inc. 45
Recombio 46
Incuron, LLC 47
Errant Gene Therapeutics, LLC 48
DEKK-TEC, Inc. 49
Ampio Pharmaceuticals, Inc. 50
Bexion Pharmaceuticals, LLC. 51
CureFAKtor Pharmaceuticals. LLC 52
Kancera AB 53
Netris Pharma S.A.S. 54
Pono Pharma 55
Tolero Pharmaceuticals, Inc. 56
Neuroblastoma - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Target 59
Assessment by Mechanism of Action 63
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
dinutuximab - Drug Profile 71
APN-311 - Drug Profile 73
APN-301 - Drug Profile 75
iobenguane I 131 - Drug Profile 77
Edotreotide Labeled Yttrium 90 - Drug Profile 79
3F8-Mab - Drug Profile 81
TPI-287 - Drug Profile 83
pazopanib hydrochloride - Drug Profile 85
Lutetium-177 Dotatate - Drug Profile 89
eflornithine hydrochloride - Drug Profile 90
perifosine - Drug Profile 92
paclitaxel - Drug Profile 95
New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile 98
Natural Killer Cell Product for Adoptive Cell-Mediated Therapy - Drug Profile 99
Neuroblastoma Vaccine - Drug Profile 101
RXDX-101 - Drug Profile 103
firtecan pegol - Drug Profile 105
NTX-010 - Drug Profile 107
racotumomab - Drug Profile 109
X-396 - Drug Profile 111
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 112
Recombinant Protein for Metastatic Melanoma and Neuroblastoma - Drug Profile 113
Cell Therapy for Neuroblastoma and Sarcomas - Drug Profile 114
LEE-011 - Drug Profile 116
Dendritic Cell Therapy for Oncology - Drug Profile 118
Tri-Virus Specific Cytotoxic T-cells - Drug Profile 119
S-588410 - Drug Profile 121
Monoclonal Antibody to Inhibit GD2 and CD3 for Neuroblastoma - Drug Profile 122
CEP-28122 - Drug Profile 123
Small Molecules to Inhibit Checkpoint Kinase 1 for Oncology - Drug Profile 124
CBL-0137 - Drug Profile 125
TH-302 - Drug Profile 126
TRBS-07 - Drug Profile 133
CG-1521 - Drug Profile 134
CFAKC-4 - Drug Profile 135
Small Molecule Targeting Netrin-1 Ligand - Drug Profile 136
BACPT-DP - Drug Profile 137
CCT-137690 - Drug Profile 138
1-B7 - Drug Profile 139
TP-0903 - Drug Profile 140
BL-8040 - Drug Profile 141
NCE-001 - Drug Profile 143
BXQ-350 - Drug Profile 144
BN-210 - Drug Profile 146
cVE-199 - Drug Profile 147
CCT-244747 - Drug Profile 148
Vaccine for Neuroblastoma - Drug Profile 149
MCT-1 Inhibitors - Drug Profile 150
Small Molecule for Oncology - Drug Profile 152
RKS-262 - Drug Profile 153
Small Molecule to Inhibit Vascular Endothelial Growth Factor for Oncology - Drug Profile 154
AMXT-1501 + eflornithine hydrochloride - Drug Profile 155
Vaccine for Neuroblastoma - Drug Profile 157
TR-100 - Drug Profile 158
FSEC - Drug Profile 159
Small Molecules to Inhibit Tm5NM1 for Cancer - Drug Profile 160
M-606 - Drug Profile 161
SRX-2523 - Drug Profile 162
Small Molecules to Inhibit Aurora Kinase and ALK Kinase for Oncology - Drug Profile 163
CFAKY-15 - Drug Profile 164
Small Molecule to Inhibit HDAC for Neuroblastoma - Drug Profile 165
Recombinant Protein to Inhibit HDAC for Neuroblastoma - Drug Profile 166
12-a - Drug Profile 167
Peptide to Inhibit Src Tyrosine Kinase for Oncology - Drug Profile 168
Drugs to Activate Caspase 3 for Oncology - Drug Profile 169
Small Molecule for Neuroblastoma - Drug Profile 170
Syrbactins - Drug Profile 171
Drugs to Inhibit HDAC for Multiple Myeloma and Neuroblastoma - Drug Profile 172
Monoclonal Antibody to Target CD3 for Neuroblastoma - Drug Profile 173
Mocolonal Antibody to Target GD2 for Neuroblastoma - Drug Profile 174
Small Molecules to Inhibit NET Transporter for Neuroblastoma - Drug Profile 175
eh8B6 - Drug Profile 176
Neuroblastoma - Recent Pipeline Updates 177
Neuroblastoma - Dormant Projects 206
Neuroblastoma - Discontinued Products 207
Neuroblastoma - Product Development Milestones 208
Featured News & Press Releases 208
Appendix 215
Methodology 215
Coverage 215
Secondary Research 215
Primary Research 215
Expert Panel Validation 215
Contact Us 216
Disclaimer 216

List of Tables
Number of Products under Development for Neuroblastoma, H2 2014 15
Number of Products under Development for Neuroblastoma - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 18
Number of Products under Development by Companies, H2 2014 (Contd..1) 19
Number of Products under Development by Companies, H2 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2014 22
Comparative Analysis by Late Stage Development, H2 2014 23
Comparative Analysis by Clinical Stage Development, H2 2014 24
Comparative Analysis by Early Stage Development, H2 2014 25
Products under Development by Companies, H2 2014 26
Products under Development by Companies, H2 2014 (Contd..1) 27
Products under Development by Companies, H2 2014 (Contd..2) 28
Products under Investigation by Universities/Institutes, H2 2014 29
Neuroblastoma - Pipeline by United Therapeutics Corporation, H2 2014 30
Neuroblastoma - Pipeline by Shionogi & Co., Ltd., H2 2014 31
Neuroblastoma - Pipeline by GlaxoSmithKline plc, H2 2014 32
Neuroblastoma - Pipeline by Gamida Cell Ltd., H2 2014 33
Neuroblastoma - Pipeline by BioLineRx, Ltd., H2 2014 34
Neuroblastoma - Pipeline by Novartis AG, H2 2014 35
Neuroblastoma - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 36
Neuroblastoma - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 37
Neuroblastoma - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 38
Neuroblastoma - Pipeline by Celgene Corporation, H2 2014 39
Neuroblastoma - Pipeline by AEterna Zentaris Inc., H2 2014 40
Neuroblastoma - Pipeline by Lorus Therapeutics Inc., H2 2014 41
Neuroblastoma - Pipeline by Novogen Limited, H2 2014 42
Neuroblastoma - Pipeline by Cleveland BioLabs, Inc., H2 2014 43
Neuroblastoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 44
Neuroblastoma - Pipeline by Sareum Holdings plc, H2 2014 45
Neuroblastoma - Pipeline by MabVax Therapeutics, Inc., H2 2014 46
Neuroblastoma - Pipeline by Bionucleon Srl, H2 2014 47
Neuroblastoma - Pipeline by Neotropix, Inc., H2 2014 48
Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2014 49
Neuroblastoma - Pipeline by Sutro Biopharma, Inc., H2 2014 50
Neuroblastoma - Pipeline by Recombio, H2 2014 51
Neuroblastoma - Pipeline by Incuron, LLC, H2 2014 52
Neuroblastoma - Pipeline by Errant Gene Therapeutics, LLC, H2 2014 53
Neuroblastoma - Pipeline by DEKK-TEC, Inc., H2 2014 54
Neuroblastoma - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 55
Neuroblastoma - Pipeline by Bexion Pharmaceuticals, LLC., H2 2014 56
Neuroblastoma - Pipeline by CureFAKtor Pharmaceuticals. LLC, H2 2014 57
Neuroblastoma - Pipeline by Kancera AB, H2 2014 58
Neuroblastoma - Pipeline by Netris Pharma S.A.S., H2 2014 59
Neuroblastoma - Pipeline by Pono Pharma, H2 2014 60
Neuroblastoma - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 61
Assessment by Monotherapy Products, H2 2014 62
Assessment by Combination Products, H2 2014 63
Number of Products by Stage and Target, H2 2014 66
Number of Products by Stage and Mechanism of Action, H2 2014 70
Number of Products by Stage and Route of Administration, H2 2014 73
Number of Products by Stage and Molecule Type, H2 2014 75
Neuroblastoma Therapeutics - Recent Pipeline Updates, H2 2014 182
Neuroblastoma - Dormant Projects, H2 2014 211
Neuroblastoma - Discontinued Products, H2 2014 212